The global demand for Multiple Sclerosis Drugs Market is presumed to reach the market size of nearly USD 39.77 BN by 2030 from USD 23.32 BN in 2022 with a CAGR of 6.9% under the study period of 2023 - 2030.
Multiple sclerosis, an autoimmune disorder, in which the myelin sheath of the central nervous system acts as a protective covering surrounding the nerve cells gets damaged and affects the coordination between the brain and the rest of the body. Some of the common symptoms associated with multiple sclerosis are spinal cord atrophy, muscle weakness, difficulty in coordination, loss of balance, visual disturbances memory and thinking problems. This disease cannot be cured. However, multiple sclerosis drugs can manage the symptoms and slow down disease progression. The drugs can be categorized as immunosuppressants, immunomodulators, interferons and others and can be administered orally as well as parenterally.
Market Dynamics
As per findings, about 2.3 million people in the world are suffering from multiple sclerosis out of which about 1 million people belongs to U.S. These figures are indicative of multiple sclerosis drugs market growth as there will be a hike in demand for MS drugs. In addition, since the number of multiple sclerosis cases continues to surge, initiatives are being taken to develop new MS drugs and therapies, spread awareness and allocate more funds for the purpose of research activities. However, high cost of treatment, expiry of drug patent and delayed hospital visits due to the Covid-19 outbreak are hindering the growth of multiple sclerosis drug market.
The report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of multiple sclerosis drugs. The growth and trends of Multiple Sclerosis Drugs Industry provide a holistic approach to this study.
Market Segmentation
This section of the multiple sclerosis drugs market report provides detailed data on the segments by analyzing them at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Drug Class
- Immunomodulators
- Immunosuppressants
- Interferons
- Others
By Route Of Administration
- Oral
- Injection (Intramuscular, Subcutaneous, Intravenous)
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Regional Analysis
This section covers the regional outlook, which accentuates current and future demand for the Multiple Sclerosis Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Multiple Sclerosis Drugs Market Share by Region (Representative Graph)
Know more about this report: Download free sample
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Multiple Sclerosis Drugs market include Biogen (U.S.), Pfizer Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Merck & Co. Inc. (U.S.), Sanofi (France), Teva Pharmaceutical Industries Ltd. (Israel), Janssen Pharmaceuticals Inc. (Johnson & Johnson Corporation) (U.S.), Bristol-Myers Squibb Company (U.S.). This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.